CD70 蛋白, Cynomolgus (HEK293, His)

CD70 is the ligand of CD27 in activated T and B lymphocytes, is an important cytokine in CD70-CD27 pathway involving with the generation and maintenance of T cell immunity^[1]. CD70 is a surface antigen, also shows antiviral activity and regulates viability of tumor cells and regulatory T cells^[2][3]. As for CD70 protein in cynomolgus contains TNF_2 domain (57-189 a.a) and transmembrane helix, belonging to the tumor necrosis factor (TNF) family. CD70 Protein, Cynomolgus (HEK293, His) is 156 amino acids in length (Q39-P194) and is expressed in the HEK293 cells with a N terminal His-tag.

CD70 (CD27 Ligand)属于肿瘤坏死因子(TNF)家族，是TNFRSF27/CD27^[1]的配体。
CD70和CD27是II型同源三聚体和I型同源二聚体跨膜糖蛋白，分别在激活的 T 淋巴细胞和静息的 T 淋巴细胞和 B 淋巴细胞上表达^[3][4]。CD70 作为一系列弥漫性大 B 细胞淋巴瘤中最常见的突变基因之一，尤其在关键的 Epstein-Barr 病毒 (EBV) 特异性 T 细胞免疫中发挥作用，更广泛地用于 B 细胞的免疫监视。CD70 通过恢复由 CD70 缺陷的 EBV 感染 B 细胞刺激的 EBV 特异性 T 淋巴细胞的扩增来抑制 EBV 感染^[3]。
CD70 参与先天性和适应性免疫的激活，在成熟树突状细胞中表达，并在 CD40 或 Toll 样受体的触发下上调^[2]。
CD70 诱导共刺激 T 细胞增殖，增强溶细胞 T 细胞的生成细胞，并有助于 T 细胞激活^[4]。
据报道，CD70 在调节 B 细胞激活、自然杀伤细胞的细胞毒功能和免疫球蛋白合成中发挥作用^[5]。使用 CAR-T 细胞靶向 CD70 阳性肿瘤可诱导有效的抗肿瘤反应^[6]。

Immobilized Cynomolgus CD27 Ligand at 2 μg/mL (100μL/Well) on the plate. Dose response curve for Cynomolgus/Rhesus macaque CD27 with the EC₅₀ of 60.8 ng/mL determined by ELISA.

Cynomolgus

HEK293

N-His

G7PYU6-1 (Q39-P194)

/

60-90 kDa

Greater than 95% as determined by Tris-Bis PAGE.

无菌粉末.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Normally 5% trehalose is added as protectant before lyophilization.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Bowman MR, et al. The cloning of CD70 and its identification as the ligand for CD27. J Immunol. 1994 Feb 15;152(4):1756-61.  [Content Brief]

  [2]. Jacobs J, et al. CD70: An emerging target in cancer immunotherapy. Pharmacol Ther. 2015 Nov;155:1-10.  [Content Brief]

  [3]. Izawa K, et al. Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. J Exp Med. 2017 Jan;214(1):73-89.  [Content Brief]

  [4]. Brown GR, et al. CD27-CD27 ligand/CD70 interactions enhance alloantigen-induced proliferation and cytolytic activity in CD8+ T lymphocytes. J Immunol. 1995 Apr 15;154(8):3686-95.  [Content Brief]

  [5]. Kobata T, et al. CD27-CD70 interactions regulate B-cell activation by T cells. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11249-53.  [Content Brief]

  [6]. Jin L, et al. CD70, a novel target of CAR T-cell therapy for gliomas. Neuro Oncol. 2018 Jan 10;20(1):55-65.  [Content Brief]